Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

In July the company announced the completion of a $255 million round led by Warburg Pincus and joined by over 25 high-profile investors, and in August,  it nominated the second preclinical candidate for kidney fibrosis. In July the company announced the completion of a$255 millionround led by Warburg Pincus and joined by over 25 high-profile investors, and in August,  it nominated the second preclinical candidate for kidney fibrosis. About Insilico Medicine Insilico...

In July the company announced the completion of a $255 million round led by Warburg Pincus and joined by over 25 high-profile investors, and in August,  it nominated the second preclinical candidate for kidney fibrosis.

About Insilico Medicine

Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company, is developing artificial intelligence platforms. These platforms use deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and ageing-related diseases. Since its inception, Insilico Medicine has raised over $300 million from reputable financial, biotechnology, and information technology investors.

Website http://insilico.com/

Media Contact

For further information, images, or interviews, please contact [email protected].

Photo - https://mma.prnewswire.com/media/1590789/Insilico_Medicine.jpg